Phase 2 Osteoarthritis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People with knee osteoarthritis that has been rated as Grade 1, 2, or 3 on a standard medical scale (called the Kellgren-Lawrence scale)
- People who have had knee osteoarthritis symptoms in one knee for at least 3 months before visiting the trial site
- People whose osteoarthritis pain is only in the affected knee, and not causing symptoms in the hips, ankles, or the other knee
- People who are able to attend and participate in physical therapy sessions
- People who speak English
Who may not be able to join:
- People who have received injection treatment into the knee for osteoarthritis within the past 6 months
- People who have osteoarthritis in one or more other major joints of the lower body that affects their daily activities
- People with a history of septic arthritis (a serious joint infection)
- People who had knee surgery specifically for osteoarthritis or cartilage problems less than one year before the trial, such as certain graft procedures, high tibial osteotomy, partial knee replacement, or kneecap resurfacing
- People who have had a total knee replacement or who have existing surgical hardware in the knee
- People with a platelet disorder or a bleeding disorder
- People with a rheumatological disease, an autoimmune condition, a weakened immune system, or an active history of cancer
- People currently taking chemotherapy, who regularly take prednisone (a steroid), or who regularly use anti-inflammatory medications
- People who are pregnant, breastfeeding, or unwilling to use birth control during the study
- People with an uncontrolled illness, physical disability, or any other condition that makes aerobic exercise unsafe or not suitable, including (but not limited to): a recent heart attack (within 5 days of any study procedure), unstable chest pain, uncontrolled heart rhythm problems, repeated fainting episodes, active heart infection, acute heart muscle or lining inflammation, severe uncontrolled aortic heart valve narrowing, uncontrolled heart failure, a blood clot in the lungs within the past 3 months, blood clots in the lower limbs, suspected tearing of a major blood vessel, uncontrolled asthma, fluid in the lungs, very low oxygen levels at rest, respiratory failure, other acute conditions that could be worsened by exercise (such as active infection, kidney failure, or thyroid problems), or a mental condition that prevents the person from being able to cooperate with the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Anthony Luke, MD, MPH, University of California, San Francisco
Phone: 415.502.4548
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Identify Protein Changes in Platelet Rich Plasma (PRP)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.